Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. [6] It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer .

Differentiation syndrome is a common condition that affects your blood cells and may be life-threatening or lead to death. Differentiation syndrome in adults with AML and MDS has happened as early as 1 day and up to 3 months after starting TIBSOVO.

On October 24, 2023, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with relapsed or refractory myelodysplastic syndromes (MDS)...

Apr 1, 2025 · Ivosidenib is used alone or together with azacitidine to treat newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years of age or older or who have health problems that prevent the use of certain cancer treatments (chemotherapy).

Apr 20, 2022 · The combination of ivosidenib — an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) — and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly...

On August 25, 2021, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally advanced or metastatic...

Ivosidenib works by blocking an abnormal enzyme that some cancer cells with specific changes in the IDH-1 gene make. Blocking the abnormal enzyme may make cancer cells differentiate to become more like normal cells and grow more slowly.

Aug 22, 2024 · What is ivosidenib? Ivosidenib targets a specific gene mutation called IDH1, which can affect your bone marrow. IDH1 mutation prevents young blood cells from developing into healthy adult blood cells, which can result in symptoms of acute myeloid leukemia (AML). Ivosidenib is for use only in adults with an IDH1 mutation.

On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as...

Ivosidenib is also called Tibsovo ®. It is a type of targeted therapy drug called a cancer growth inhibitor. Ivosidenib is used to treat bile duct cancer (cholangiocarcinoma). You may be given ivosidenib if the cancer has a change (mutation) in a gene called IDH1.